[go: up one dir, main page]

SG11201805784PA - Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases - Google Patents

Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases

Info

Publication number
SG11201805784PA
SG11201805784PA SG11201805784PA SG11201805784PA SG11201805784PA SG 11201805784P A SG11201805784P A SG 11201805784PA SG 11201805784P A SG11201805784P A SG 11201805784PA SG 11201805784P A SG11201805784P A SG 11201805784PA SG 11201805784P A SG11201805784P A SG 11201805784PA
Authority
SG
Singapore
Prior art keywords
international
rule
protein
english
pct
Prior art date
Application number
SG11201805784PA
Inventor
Jeffrey Greve
Original Assignee
Delinia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delinia Inc filed Critical Delinia Inc
Publication of SG11201805784PA publication Critical patent/SG11201805784PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/127514 Al 27 July 2017 (27.07.2017) WIPO I PCT (51) International Patent Classification: C07K 14/55 (2006.01) C07K 16/46 (2006.01) C07K 14/00 (2006.01) (21) International Application Number: PCT/US2017/014090 (22) International Filing Date: 19 January 2017 (19.01.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 15/002,144 20 January 2016 (20.01.2016) US (71) Applicant: DELINIA, INC. [US/US]; 400 Technology Square, 10th Floor, Cambridge, Massachusetts 02139 (US). (72) Inventor: GREVE, Jeffrey; 1066 Park Hills Road, Berke- ley, California 94708 (US). (74) Agents: KRIKELIS, Basil, S. et al.; McCarter & English, LLP, Renaissance Centre, 405 N. King Street, 8th Floor, Published: Wilmington, DE 19801 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) = (54) Title: MOLECULES THAT SELECTIVELY ACTIVATE REGULATORY T CELLS FOR THE TREATMENT OF AUTOIM- MUNE DISEASES PEPTIDE LINKER (57) : This invention provides for a fusion protein between an IL2a13y Selective Agonist protein (IL2 Selective Agonist) and a IgG Fc protein using a linker. The IL2 Selective Agonist moiety provides a therapeutic activity by selectively activating the IL2a[3y form of the receptor, thus selectively stimulating Tregs. The Fc moiety provides a prolonged circulating half-life compared to the circulating half-life of IL-2 or an IL2SA protein. 111111111111011011111111111010111110 III 011101011111H 010111111111110111111 W O 20 17 / 1275 14 Al FIG. 2 X-Fc
SG11201805784PA 2016-01-20 2017-01-19 Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases SG11201805784PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/002,144 US20170204154A1 (en) 2016-01-20 2016-01-20 Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
PCT/US2017/014090 WO2017127514A1 (en) 2016-01-20 2017-01-19 Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases

Publications (1)

Publication Number Publication Date
SG11201805784PA true SG11201805784PA (en) 2018-08-30

Family

ID=59314394

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201805784PA SG11201805784PA (en) 2016-01-20 2017-01-19 Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases

Country Status (16)

Country Link
US (7) US20170204154A1 (en)
EP (1) EP3405482A4 (en)
JP (2) JP6983787B2 (en)
KR (1) KR20180100237A (en)
CN (1) CN108602871A (en)
AU (2) AU2017210187B2 (en)
BR (1) BR112018014671A2 (en)
CA (1) CA3010621A1 (en)
CL (1) CL2018001951A1 (en)
CO (1) CO2018008558A2 (en)
EA (1) EA201891656A1 (en)
EC (1) ECSP18062614A (en)
MX (1) MX2018008840A (en)
SG (1) SG11201805784PA (en)
WO (1) WO2017127514A1 (en)
ZA (1) ZA201804458B (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX378790B (en) * 2014-07-21 2025-03-10 Delinia Inc MOLECULES THAT SELECTIVELY ACTIVATE REGULATORY T CELLS FOR THE TREATMENT OF AUTOIMMUNE DISEASES.
US20170204154A1 (en) * 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
WO2018089420A1 (en) * 2016-11-08 2018-05-17 Delinia, Inc. Il-2 variants for the treatment of autoimmune diseases
JP7165717B2 (en) 2017-03-15 2022-11-04 パンディオン・オペレーションズ・インコーポレイテッド target immune tolerance
US11879014B2 (en) 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
US10676516B2 (en) 2017-05-24 2020-06-09 Pandion Therapeutics, Inc. Targeted immunotolerance
JOP20190271A1 (en) 2017-05-24 2019-11-21 Novartis Ag Cytokine-Encapsulated Proteins - Antibody and Methods for Use for Immune-Related Disorders
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
CA3115461A1 (en) * 2018-03-09 2019-09-12 AskGene Pharma, Inc. Novel cytokine prodrugs
US10745485B2 (en) 2018-03-13 2020-08-18 Tusk Therapeutics Ltd. Anti-CD25 antibody agents
TWI853807B (en) 2018-03-28 2024-09-01 美商必治妥美雅史谷比公司 Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
CN112534052B (en) 2018-07-25 2024-09-20 奥美药业有限公司 New IL-21 prodrug and method of use
EP3833679A1 (en) 2018-08-06 2021-06-16 Medikine, Inc. Il-2 receptor binding compounds
EP3856764A4 (en) 2018-09-27 2022-11-02 Xilio Development, Inc. MASKED CYTOKINE POLYPEPTIDES
SG11202104120VA (en) * 2018-10-31 2021-05-28 Delinia Inc Multivalent regulatory t cell modulators
CN114679909A (en) 2019-05-20 2022-06-28 潘迪恩运营公司 MAdCAM-targeted immune tolerance
US11845801B2 (en) 2019-06-12 2023-12-19 AskGene Pharma, Inc. IL-15 prodrugs and methods of use thereof
EP4004025A1 (en) 2019-07-26 2022-06-01 Visterra, Inc. Interleukin-2 agents and uses thereof
KR20220044834A (en) * 2019-08-15 2022-04-11 사이팀 테라퓨틱스, 인크. Modified Interleukin 2 (IL-2) Polypeptides, Conjugates and Uses Thereof
KR20220066116A (en) * 2019-09-16 2022-05-23 젠순 (상하이) 사이언스 앤드 테크놀로지 캄파니 리미티드 Recombinant human neuregulin derivatives and uses thereof
MX2022005404A (en) 2019-11-05 2022-09-09 Medikine Inc Dual il-2r and il-7r binding compounds.
JP7427286B2 (en) 2019-11-05 2024-02-05 メディカイン、インコーポレイテッド IL-2RβγC binding compound
US12091440B2 (en) 2019-12-20 2024-09-17 Regeneron Pharmaceuticals, Inc. IL2 and peptide-MHC complex fusion proteins and methods of use thereof
KR20220140514A (en) 2020-01-10 2022-10-18 브라이트 피크 테라퓨틱스 아게 Modified IL-2 polypeptides and uses thereof
MX2022009390A (en) 2020-02-03 2022-11-16 Medikine Inc IL-7Rαγc BINDING COMPOUNDS.
WO2021158619A1 (en) 2020-02-03 2021-08-12 Medikine, Inc. IL-7Rα BINDING COMPOUNDS
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
GB2621482B (en) 2020-05-13 2024-09-04 Bonum Therapeutics Inc Compositions of protein complexes and methods of use thereof
TWI815194B (en) * 2020-10-22 2023-09-11 美商基利科學股份有限公司 INTERLEUKIN-2-Fc FUSION PROTEINS AND METHODS OF USE
CA3195260A1 (en) 2020-10-29 2022-05-05 Bristol-Myers Squibb Company Fusion proteins for the treatment of disease
JP2023553323A (en) 2020-11-25 2023-12-21 エクシリオ デベロップメント， インコーポレイテッド Tumor-specific cleavable linker
CA3203977A1 (en) 2020-12-04 2022-06-09 Visterra, Inc. Methods of using interleukin-2 agents
TW202317623A (en) 2021-06-14 2023-05-01 美商再生元醫藥公司 Il2-based therapeutics and methods of use thereof
CN113789346A (en) * 2021-08-25 2021-12-14 北京伟德杰生物科技有限公司 Long-acting recombinant human interleukin 2 fusion protein and preparation method and application thereof
KR20240148001A (en) * 2022-02-11 2024-10-10 비스테라, 인크. Interleukin-2 mutein for the treatment of autoimmune diseases
US11999771B2 (en) 2022-04-07 2024-06-04 Medikine, Inc. IL-7Rαγc ligand immunoglobulin fusion proteins
WO2024054868A1 (en) * 2022-09-07 2024-03-14 Xencor, Inc. An il-2 fc fusion protein for use in methods for the treatment of plaque psoriasis and atopic dermatitis
CN121002050A (en) * 2023-02-21 2025-11-21 艾诺康医药公司 Polynucleotides encoding modified interleukin-2 (IL2) peptides and their preparation and use

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4853332A (en) 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5466447A (en) 1988-06-29 1995-11-14 Amgen Inc. Method for treating psoriasis
JPH03500415A (en) 1988-07-05 1991-01-31 アムジエン・インコーポレーテツド interleukin 2 analogue
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5089261A (en) 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US6541610B1 (en) 1989-09-05 2003-04-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
US5650150A (en) 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
WO1995008340A1 (en) 1993-09-21 1995-03-30 Amgen Inc. Method for treating psoriasis
CZ20003099A3 (en) 1998-02-25 2002-04-17 Lexigen Pharmaceuticals Corporation Enhancing the circulating half-life of antibody-based fusion proteins
FI104522B (en) 1998-04-28 2000-02-15 Abb Control Oy Fused switch
US6955807B1 (en) 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
DZ2788A1 (en) 1998-05-15 2003-12-01 Bayer Ag Selective IL-2 agonists and antagonists.
US6348192B1 (en) 1999-05-11 2002-02-19 Bayer Corporation Interleukin-2 mutein expressed from mammalian cells
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
WO2001062827A2 (en) 2000-02-22 2001-08-30 Shearwater Corporation N-maleimidyl polymer derivatives
US6689353B1 (en) 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
AU2001292645A1 (en) 2000-09-14 2002-03-26 Beth Israel Deaconess Medical Center, Inc. Modulation of IL-2- and IL-15-mediated T cell responses
BR0207854A (en) 2001-03-07 2004-08-24 Merck Patent Gmbh Expression technology for proteins containing a hybrid isotype antibody moiety
BR0211071A (en) 2001-07-11 2004-12-21 Maxygen Holdings Ltd Polypeptide conjugate showing g-csf activity, method for preparing a g-csf conjugate, composition, method for treating a mammal suffering from an insufficient neutrophilic level, and use of the polypeptide conjugate
EP1421187B1 (en) 2001-07-27 2007-10-10 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Systems for in vivo site-directed mutagenesis using oligonucleotides
CA2456470A1 (en) 2001-08-13 2003-02-27 University Of Southern California Interleukin-2 mutants with reduced toxicity
PL206975B1 (en) 2001-12-04 2010-10-29 Merck Patent Gmbh Immunocytokines with modulated selectivity
US7452968B2 (en) 2003-01-02 2008-11-18 University Of Southern California Secreted protein factor and cell membrane-bound splice variant
ATE525395T1 (en) 2003-06-12 2011-10-15 Lilly Co Eli FUSION PROTEINS OF GLP-1 ANALOGS
US7569215B2 (en) 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
EP1925626A1 (en) 2003-07-21 2008-05-28 Transgene S.A. Novel multifunctional cytokines
ATE554108T1 (en) * 2003-07-25 2012-05-15 Amgen Inc PROCEDURES REGARDING LDCAM AND CRTAM
JP2007527242A (en) 2004-03-05 2007-09-27 カイロン コーポレーション In vitro test system for predicting patient tolerance of therapeutic agents
JP2008528621A (en) 2005-01-27 2008-07-31 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド Methods for treating renal cell carcinoma
PL1688146T3 (en) 2005-02-07 2007-12-31 Novartis Vaccines & Diagnostics Inc Preparing aldesleukin for pharmaceutical use
AU2007305443B2 (en) * 2006-09-29 2012-08-23 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
FR2918770B1 (en) 2007-07-10 2009-09-11 Essilor Int DISPLAY TO BE INTEGRATED WITH A PAIR OF EYEWEAR.
WO2009061853A2 (en) 2007-11-05 2009-05-14 Massachusetts Institute Of Technology Mutant interleukin-2 (il-2) polypeptides
DE102008023820A1 (en) 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg An agent for the treatment and / or prophylaxis of an autoimmune disease and for the production of regulatory T cells
EP2382228B2 (en) 2009-01-21 2026-01-07 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
ES2572728T3 (en) 2009-03-20 2016-06-02 F. Hoffmann-La Roche Ag Bispecific anti-HER antibodies
CN102482324B (en) * 2009-06-15 2014-07-02 拜欧肯疗法有限公司 Novel chemokine binding polypeptides capable of inhibiting the course of autoimmunity, inflammation and cancer
PL2542590T5 (en) 2010-03-05 2020-08-10 The Johns Hopkins University Compositions and Methods for Target Immunomodulatory Antibodies and Fusion Proteins
CU23923B1 (en) 2010-11-12 2013-07-31 Ct De Inmunología Molecular POLYPEPTIDES DERIVED FROM IL-2 WITH AGONIST ACTIVITY
KR20200070407A (en) 2010-11-12 2020-06-17 넥타르 테라퓨틱스 Conjugates of an il-2 moiety and a polymer
CN102462837B (en) 2010-11-19 2016-08-03 生物林格斯Ip有限公司 Anti-inflammatory composition
CA2860170C (en) 2010-12-22 2022-06-14 The Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
CN102174111B (en) 2011-01-25 2013-01-09 江苏省弗泰生物科技有限公司 Human interleukin-2 (IL-2)/Fc fusion protein and uses
TWI666027B (en) 2011-02-10 2019-07-21 羅齊克雷雅公司 Mutant interleukin-2 polypeptides
BR112013023151A2 (en) 2011-03-11 2020-09-15 Assistance Publique - Hôpitaux De Paris interleukin-2 for use in the treatment of autoimmune, immune-related or inflammatory disorder and method for determining whether a regimen or dose of il-2 needs to be modified
EA201892619A1 (en) 2011-04-29 2019-04-30 Роше Гликарт Аг IMMUNOCONJUGATES CONTAINING INTERLEUKIN-2 MUTANT POLYPETIPS
WO2013177187A2 (en) 2012-05-22 2013-11-28 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
US20140044675A1 (en) * 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
JP2014094898A (en) * 2012-11-07 2014-05-22 Univ Of Tsukuba MEDICINE COMPRISING ACTIVE MODULATOR OF CD300a-EXPRESSING CELL ASSOCIATED WITH INFLAMMATORY BOWEL DISEASE, CD300a GENE KNOCK-OUT MOUSE, AND USE OF ACTIVE MODULATOR OF CD300a-EXPRESSING CELL
US9546203B2 (en) * 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
EP3421495A3 (en) * 2013-03-15 2019-05-15 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
CN103193887B (en) 2013-04-03 2015-02-04 江苏众红生物工程创药研究院有限公司 Recombinant porcine IL2-Fc (interteukin-2-Fc) fusion protein as well as encoding gene and expressing method of fusion protein
WO2014201378A1 (en) 2013-06-13 2014-12-18 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il -2 and adoptive cell therapy
EP3508496A1 (en) 2014-02-06 2019-07-10 F. Hoffmann-La Roche AG Interleukin-2 fusion proteins and uses thereof
EP3134102B1 (en) 2014-04-24 2019-07-03 The Board of Trustees of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
KR20150133576A (en) 2014-05-20 2015-11-30 삼성전자주식회사 Chemically modified targeting protein and use thereof
MX378790B (en) 2014-07-21 2025-03-10 Delinia Inc MOLECULES THAT SELECTIVELY ACTIVATE REGULATORY T CELLS FOR THE TREATMENT OF AUTOIMMUNE DISEASES.
EP3482766B1 (en) 2014-08-11 2020-05-20 Delinia, Inc. Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
US20170224777A1 (en) 2014-08-12 2017-08-10 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
JP6941561B2 (en) 2014-10-09 2021-09-29 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Multiple variable IL-2 dose regimens for treating immune disorders
US20170204154A1 (en) * 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
CN109071623B (en) 2016-05-04 2022-05-27 美国安进公司 Interleukin-2 muteins for expansion of T regulatory cells
WO2018089420A1 (en) 2016-11-08 2018-05-17 Delinia, Inc. Il-2 variants for the treatment of autoimmune diseases

Also Published As

Publication number Publication date
AU2021257949A1 (en) 2021-11-25
CN108602871A (en) 2018-09-28
CA3010621A1 (en) 2017-07-27
US11535657B2 (en) 2022-12-27
ZA201804458B (en) 2019-09-25
EP3405482A1 (en) 2018-11-28
JP2019507589A (en) 2019-03-22
US10766938B2 (en) 2020-09-08
JP6983787B2 (en) 2021-12-17
US20190202881A1 (en) 2019-07-04
EA201891656A1 (en) 2018-12-28
US10875901B2 (en) 2020-12-29
EP3405482A4 (en) 2019-06-26
CL2018001951A1 (en) 2018-12-28
US20170204154A1 (en) 2017-07-20
US10294287B2 (en) 2019-05-21
AU2017210187A1 (en) 2018-07-19
WO2017127514A1 (en) 2017-07-27
JP2022058337A (en) 2022-04-12
BR112018014671A2 (en) 2018-12-11
US20200115429A1 (en) 2020-04-16
ECSP18062614A (en) 2018-10-31
CO2018008558A2 (en) 2018-08-21
KR20180100237A (en) 2018-09-07
US20190153058A1 (en) 2019-05-23
US20210070828A1 (en) 2021-03-11
AU2017210187B2 (en) 2021-10-07
US20190202882A1 (en) 2019-07-04
US20180037624A1 (en) 2018-02-08
MX2018008840A (en) 2018-11-09
US10774126B2 (en) 2020-09-15

Similar Documents

Publication Publication Date Title
SG11201805784PA (en) Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201810023QA (en) Anti-tim-3 antibodies and methods of use thereof
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201804673WA (en) Novel anti-claudin antibodies and methods of use
SG11201900677SA (en) Combination therapies of chimeric antigen receptors adn pd-1 inhibitors
SG11201906319XA (en) Compositions and methods for the depletion of cd137+ cells
SG11201808261RA (en) Genetic variant-phenotype analysis system and methods of use
SG11201811290VA (en) Compositions and methods for the depletion of cd117+cells
SG11201809336QA (en) Anti-pd-l1 antibodies
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201809751XA (en) Egfr inhibitor compounds
SG11201807597UA (en) Methods of treating depression using orexin-2 receptor antagonists
SG11201804787UA (en) Human immunodeficiency virus neutralizing antibodies
SG11201808724SA (en) Anti-tim-3 antibodies and compositions
SG11201907867TA (en) Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
SG11201805253SA (en) Compositions and methods related to multimodal therapeutic cell systems for cancer indications
SG11201807538PA (en) Crispr-cpf1-related methods, compositions and components for cancer immunotherapy
SG11201805792PA (en) Chimeric proteins and methods of regulating gene expression
SG11201807286WA (en) Methods and compositions for transducing lymphocytes and regulated expansion thereof